Cytokine Secretion Pattern in Treatment of Lymphocytes of Multiple Sclerosis Patients with Fumaric Acid Esters

REFERENCES

• Asadullah, K., Schmid, H., Friedrich, M., Randow, F., Volk, H. D., Sterry, W., (1997). Influence of monomethylfumarate on monocytic cytokine formation—Explanation for adverse and therapeutic effects in psoriasis? Arch. Dermatol. Res. 289:623–630.
   PubMed Web of Science ®Google Scholar
• Axtell, R. C., de Jong, B. A., Boniface, K., van der Voort, L. F., Bhat, R., De Sarno, P., (2010). T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16:406–412.
   PubMed Web of Science ®Google Scholar
• Bielekova, B. M. R. (2004). Development of biomarkers in multiple sclerosis. Brain 127:1463–1478.
   PubMed Web of Science ®Google Scholar
• Birnbaum, G. (2010) Current and future treatments for relapsing-remitting multiple sclerosis. Curr. Opin. Drug Discov. Devel. 13:214–225.
   Google Scholar
• Bovenschen, H. J., Langewouters, A. M., van de Kerkhof, P. C. (2010). Dimethylfumarate for psoriasis: Pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study. Am. J. Clin. Dermatol. 16. [Epub ahead of print]
   Google Scholar
• Ehling, R., Berger, T., Reindl, M. (2010). Multiple sclerosis—Established and novel therapeutic approaches. Cent. Nerv. Syst. Agents Med. Chem. 10:3–15.
   Google Scholar
• Ghoreschi, K., Rocken, M. (2004). Immune deviation strategies in the therapy of psoriasis. Curr. Drug Targets Inflamm. Allergy 3:193–198.
   PubMedGoogle Scholar
• Goverman, J. (2009) Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9:393–407.
   PubMed Web of Science ®Google Scholar
• Hedegaard, C. J., Krakauer, M., Bendtzen, K., Lund, H., Sellebjerg, F., Nielsen, C.H. (2008). T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 125:161–169.
   PubMed Web of Science ®Google Scholar
• de Jong, R., Bezemer, A.C., Zomerdijk, T.P., van de Pouw-Kraan, Ottenhoff, T. H., Nibbering, P. H. (1996). Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol. 26:2067–2074.
   PubMed Web of Science ®Google Scholar
• Kappos, L., Gold, R., Miller, D. H., Macmanus, D. G., Havrdova, E., Limmroth, V., (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372:1463–1472.
   PubMed Web of Science ®Google Scholar
• Lee, D. H., Linker, R. A., Gold, R. (2008) Spotlight on fumarates. Int. MS J. 15:12–18.
   Google Scholar
• Linker, R. A., Lee, D. H., Stangel, M., Gold, R. (2008). Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Expert Rev Neurother. 8:1683–1690.
   PubMedGoogle Scholar
• Litjens, N. H., Rademaker, M., Ravensbergen, B., Rea, D., van der Plas, M. J., Thio, B., (2004). Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur. J. Immunol. 34:565–575.
   PubMed Web of Science ®Google Scholar
• Litjens, N. H., Rademaker, M., Ravensbergen, B., Thio, H. B., van Dissel, J.T., Nibbering, P. H. (2006) Effects of monomethylfumarate on dendritic cell differentiation. Br. J. Dermatol. 154:211–217.
   PubMed Web of Science ®Google Scholar
• Loewe, R., Holnthoner, W., Groger, M., Pillinger, M., Gruber, F., Mechtcheriakova, D., (2002). Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J. Immunol. 168:4781–4787.
   PubMed Web of Science ®Google Scholar
• Lopez-Diego, R. S., Weiner, H. L. (2008). Novel therapeutic strategies for multiple sclerosis—Multifaceted adversary. Nat. Rev. Drug Discov. 7:909–925.
   PubMed Web of Science ®Google Scholar
• Moharregh-Khiabani, D., Linker, R. A., Gold, R., Stangel, M. (2009). Fumaric acid and its esters: an emerging treatment for multiple sclerosis. Curr. Neuropharmacol. 7:60–64.
   PubMed Web of Science ®Google Scholar
• Mrowietz, U., Christophers, E., Altmeyer, P. (1998) Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br. J. Dermatol. 138:456–460.
   PubMed Web of Science ®Google Scholar
• Ockenfels, H. M., Schultewolter, T., Ockenfels, G., Funk, R., Goos, M. (1998). The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br. J. Dermatol. 139:390–395.
   PubMed Web of Science ®Google Scholar
• Rostami-Yazdi, M., Clement, B., Mrowietz, U. (2010) Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res. 24 [Epub ahead of print]
   Google Scholar
• Schilling, S., Goelz, S., Linker, R., Luehder, F., Gold, R. (2006) Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 145:101–107.
   PubMed Web of Science ®Google Scholar
• Schimrigk, S., Brune, N., Hellwig, K., Lukas, C., Bellenberg, B., Rieks, M., (2006). Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur. J. Neurol. 13:604–610.
   PubMed Web of Science ®Google Scholar
• Yazdi, M. R., Mrowietz, U. (2008). Fumaric acid esters. Clin.Dermatol. 26:522–526.
   PubMed Web of Science ®Google Scholar
• Zhu, K., Mrowietz, U. (2001). Inhibition of dendritic cell differentiation by fumaric acid esters. J. Invest. Dermatol. 116:203–208.
   PubMed Web of Science ®Google Scholar